All In Biotech

Drug Trial Radar · NCT06714591

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

A Multicenter, Open-Label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia.

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

52

Actual

Start

Dec 19, 2024

Primary completion

Sep 16, 2026

Study completion Sep 16, 2026

Sponsor

Lead sponsor
SystImmune Inc.Industry
Sponsor type
Industry
First posted
Dec 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.

Conditions

  • Relapsed/Refractory Acute Myeloid Leukemia

Interventions

  • BL-M11D1Drug

    The study includes 2 parts: Part 1 Dose escalation and Dose Finding

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants with dose-limiting toxicitiesTime frame: 1 Year
  2. Participants with Serious Adverse Events (SAEs) and treatment-emergent adverse events (TEAEs)Time frame: 1 Year
  3. To determine the minimum safe and effective dose (MSED), maximum tolerated dose (MTD) if reached, and maximum administered dose (MAD) of BL-M11D1 in AMLTime frame: 1 Year

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • UCLA Ronald Reagan Medical Center

    Los Angeles, California

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado

  • Yale Cancer Center, Smilow Cancer Hospital at Yale New Haven

    New Haven, Connecticut

  • Moffitt Cancer Center

    Tampa, Florida

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland

  • START Midwest/The Cancer and Hematology Center

    Grand Rapids, Michigan

  • John Theurer Cancer Center-Hackensack

    Hackensack, New Jersey

  • Oncology Hematology Care Clinical Trials, LLC

    Cincinnati, Ohio

  • The Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • WVCI Oncology Associates of Oregon

    Eugene, Oregon

  • Oregon Health and Science University

    Portland, Oregon

  • Temple Health Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • SCRI -TriStar BMT

    Nashville, Tennessee

  • MD Anderson Cancer Center

    Houston, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Fred Hutchinson Cancer Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.